A company called DBV Technologies announced that their peanut allergy patch, Viaskin, worked well in a recent trial. This is good news because the U.S. Food and Drug Administration (FDA) had previously rejected the patch in 2020. The FDA had asked for changes to make the patch stick better to the skin and wanted more proof that it works. Now, with successful trial results, DBV plans to ask the FDA for approval in the first half of next year. The patch is meant for children aged 4 to 7. The FDA has already given this treatment special status, which might speed up its review. DBV has faced several challenges with this patch. In 2017, a study didn’t meet its main goal, and the company withdrew its FDA application in 2018 due to manufacturing concerns. After another rejection in 2020, DBV started a new trial in late 2021 to address the FDA’s concerns. The company also faced a temporary pause in the trial in 2022 but continued with its plans. Viaskin works by delivering a tiny amount of peanut protein through the skin. The goal is to train the immune system to tolerate peanuts better, reducing allergic reactions. The recent trial, called Vitesse, is the largest study ever done on a food allergy treatment. It included 654 children who either got the patch or a placebo. After 12 months, about 47% of the children using Viaskin could handle more peanut exposure without a reaction, compared to 15% in the placebo group. The most common side effects were mild skin reactions to the patch. Two children had severe allergic reactions but continued the treatment. Overall, there were no serious side effects. Another peanut allergy treatment, Palforzia, was approved by the FDA in 2020. However, its use has been limited due to the COVID-19 pandemic, concerns about allergic reactions, and dosing requirements. Nestlé Health Science bought the company that makes Palforzia in 2020 but sold it three years later. The new owner has continued developing Palforzia, but they plan to stop making it by July 31, 2026. DBV’s stock price jumped to over $25 on Wednesday, a big increase from late last year when it was below $3.